These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37168900)

  • 1. Hypersensitivity Reaction to Ustekinumab in Pediatric and Young Adult Inflammatory Bowel Disease Patients: A Case Series.
    Sunny J; Fonseca AG; Crim AM; Goyal A; Felipez LM
    JPGN Rep; 2022 May; 3(2):e205. PubMed ID: 37168900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of ustekinumab in treatment of ulcerative colitis: a narrative review.
    Grova M; Vitello A; Mannino M; Casà A; Renna S; Macaluso FS; Orlando A
    Immunotherapy; 2023 Dec; 15(18):1539-1552. PubMed ID: 38018475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease.
    Kakiuchi T; Kimura S; Esaki M; Matsuo M
    Front Pediatr; 2021; 9():670703. PubMed ID: 35004530
    [No Abstract]   [Full Text] [Related]  

  • 4. Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease.
    Krugliak Cleveland N; Masching A; Rubin DT
    ACG Case Rep J; 2020 Aug; 7(8):e00449. PubMed ID: 32904020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
    Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
    BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
    Romero RK; Magro DO; Queiroz NSF; Damião AOMC; Teixeira FV; Nones RB; Sassaki LY; Saad-Hossne R; Kotze PG
    Gastroenterol Hepatol; 2022; 45(7):499-506. PubMed ID: 34634427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series.
    Phillips FM; Verstockt B; Sebastian S; Ribaldone D; Vavricka S; Katsanos K; Slattery E; de Suray N; Flores C; Fries W; Vincenzi F; Capoferro E; Bachmann O; Kopylov U
    J Crohns Colitis; 2020 Oct; 14(10):1488-1493. PubMed ID: 32318735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis.
    Yoshihara T; Shinzaki S; Amano T; Iijima H; Takehara T; Inoue N; Uchino M; Esaki M; Kobayashi T; Saruta M; Sugimoto K; Nakamura S; Hata K; Hirai F; Hiraoka S; Fujii T; Matsuura M; Matsuoka K; Watanabe K; Nakase H; Watanabe M
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1744-1753. PubMed ID: 33450096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ustekinumab Does Not Increase Risk of Adverse Events: A Meta-Analysis of Randomized Controlled Trials.
    Rolston VS; Kimmel J; Popov V; Bosworth BP; Hudesman D; Malter LB; Hong S; Chang S
    Dig Dis Sci; 2021 May; 66(5):1631-1638. PubMed ID: 32445049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children's hospital in Japan.
    Takeuchi I; Arai K; Kyodo R; Sato T; Tokita K; Hirano Y; Shimizu H
    J Gastroenterol Hepatol; 2021 Jan; 36(1):125-130. PubMed ID: 32497325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Long-Term Clinical Effectiveness of Ustekinumab in Antitumor Necrosis Factor-Experienced Crohn's Disease Patients.
    Altuwaijri M; Hakami L; Alharbi O; Almadi M; Alshankiti S; Aljebreen A; Azzam N
    Cureus; 2022 Aug; 14(8):e28536. PubMed ID: 36185868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn's Disease.
    Globig AM; Sommer NP; Wild K; Schardey J; Zoldan K; Thomann AK; Schulte LA; Schreiner R; Reindl W; Klaus J; Schempp CM; Hofmann M; Thimme R; Boettler T; Hasselblatt P
    Cell Mol Gastroenterol Hepatol; 2021; 11(1):1-12. PubMed ID: 32679193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of ustekinumab in Crohn's disease.
    Kotze PG; Ma C; Almutairdi A; Panaccione R
    J Inflamm Res; 2018; 11():35-47. PubMed ID: 29445293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
    Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ustekinumab in Crohn's disease: effectiveness and safety in clinical practice.
    Saldaña Dueñas C; Rullán Iriarte M; Elosua González A; Rodríguez Gutiérrez C; Rubio Iturria S; Nantes Castillejo Ó
    Gastroenterol Hepatol; 2020 Nov; 43(9):497-505. PubMed ID: 32703654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
    Blesl A; Petritsch W; Binder L; Fürst S; Wenzl H; Baumann-Durchschein F; Kump P; Högenauer C
    Scand J Gastroenterol; 2022 Nov; 57(11):1327-1330. PubMed ID: 35732583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response.
    Heron V; Li Fraine S; Panaccione N; Restellini S; Germain P; Candido K; Bernstein CN; Bessissow T; Bitton A; Chauhan UK; Lakatos PL; Marshall JK; Michetti P; Seow CH; Rosenfeld G; Panaccione R; Afif W
    J Can Assoc Gastroenterol; 2022 Oct; 5(5):208-213. PubMed ID: 36196277
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.